PetCure Oncology says it has treated more than 10,000 patients

CURRENT BRIEF VERSION: PetCure Oncology says it has now treated more than 10,000 patients with radiation therapy, a milestone the company is framing as evidence of how much access to veterinary radiation oncology has expanded over the past decade. In its January 7 announcement, the Thrive Pet Healthcare-affiliated network said it was founded in 2015 to bring stereotactic radiosurgery and stereotactic radiation therapy beyond academic centers and into a broader referral setting. PetCure says those protocols can often be completed in one to three sessions, compared with much longer conventional courses, and that its network now operates multiple U.S. centers with another technology upgrade planned in Seattle. The company has also been signaling where it sees the field going next, including mobile radiation systems that may not require a dedicated vault and could allow CT, treatment planning, and treatment delivery under a single anesthetic event for some cases. (petcureoncology.com)

Why it matters: For veterinary professionals, the story is less about a round-number milestone than about referral access. When PetCure launched, the company said fewer than 10 U.S. specialty centers offered stereotactic radiosurgery for pets, and PetCure’s own veterinarian-facing materials say there were fewer than 70 traditional veterinary radiation facilities in the country at the time. In company commentary, chief medical officer Neal Mauldin has argued that limited specialist and technology access, especially outside major population centers, helped drive development of stereotactic protocols that can be delivered in days rather than weeks for families traveling long distances. Today, the Veterinary Cancer Society lists a much broader national map of radiation facilities, underscoring how access has grown, even if it remains uneven by geography and specialist availability. For general practitioners, that means radiation may be a more realistic option for selected oncology cases than it was a decade ago, especially when shorter treatment courses can reduce anesthetic events, travel burden, and time away from the primary care team. PetCure is also pointing to adjacent growth areas including radiation-immunotherapy combinations, low-dose radiation for chronic inflammatory conditions such as feline cystitis, stomatitis, and osteoarthritis, and low dose-rate radiation therapy as a potential add-on in canine B-cell lymphoma protocols. (petcureoncology.com)

What to watch: Watch whether PetCure’s next phase centers on new site openings, new platform rollouts like the Sirius system in Seattle, and more published outcomes data that could further shape referral patterns—not just for stereotactic radiation, but also for newer approaches the company has highlighted, such as immunotherapy combinations and low dose-rate protocols. (empyreanmed.com)